T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fidelity National Information Services
FIS
|
+$3.15B |
| 2 |
Global Payments
GPN
|
+$2B |
| 3 |
NextEra Energy
NEE
|
+$1.82B |
| 4 |
Salesforce
CRM
|
+$1.51B |
| 5 |
Boeing
BA
|
+$1.38B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
WP
Worldpay, Inc.
WP
|
+$3.23B |
| 2 |
DATA
Tableau Software, Inc.
DATA
|
+$1.76B |
| 3 |
TSS
Total System Services, Inc.
TSS
|
+$1.49B |
| 4 |
Bank of America
BAC
|
+$1.43B |
| 5 |
Elevance Health
ELV
|
+$1.39B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.68% |
| 2 | Healthcare | 15.83% |
| 3 | Financials | 13.92% |
| 4 | Consumer Discretionary | 13.43% |
| 5 | Industrials | 10.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
FMC
FMC
$1.27B
| $21.5M | ﹤0.01% |
245,564
-8,403
| -3% | -$721K |
|
1127
First American
FAF
$7.56B
| $21.5M | ﹤0.01% |
364,050
-787,378
| -68% | -$45.1M |
|
|
CHCT
1128
Community Healthcare Trust
CHCT
$433M
| $21.5M | ﹤0.01% |
481,648
+1,413
| +0.3% | +$59.5K |
|
1129
Ponce Financial Group
PDLB
$501M
| $21.4M | ﹤0.01% |
2,126,955
+503
| +0% | +$5.12K |
|
1130
Pinnacle West Capital
PNW
$12.2B
| $21.3M | ﹤0.01% |
219,742
+1,341
| +0.6% | +$126K |
|
|
ZGNX
1131
DELISTED
Zogenix, Inc.
ZGNX
| $21.3M | ﹤0.01% |
531,058
-289,091
| -35% | -$13.3M |
|
|
GRMN
1132
Garmin
GRMN
$60.2B
| $21.2M | ﹤0.01% |
250,555
+48,495
| +24% | +$3.91M |
|
1133
Mohawk Industries
MHK
$9.42B
| $21.2M | ﹤0.01% |
170,939
-13,482
| -7% | -$1.73M |
|
|
APLS
1134
DELISTED
Apellis Pharmaceuticals
APLS
| $21.1M | ﹤0.01% |
874,412
+175,200
| +25% | +$4.82M |
|
1135
Southern First Bancshares
SFST
$612M
| $21.1M | ﹤0.01% |
528,493
+6,019
| +1% | +$234K |
|
1136
Orion
OEC
$360M
| $21M | ﹤0.01% |
1,255,507
+24,274
| +2% | +$397K |
|
1137
Supernus Pharmaceuticals
SUPN
$2.74B
| $20.9M | ﹤0.01% |
759,625
-12,160
| -2% | -$360K |
|
1138
Culp Inc
CULP
$43.2M
| $20.8M | ﹤0.01% |
1,275,881
-331,040
| -21% | -$5.5M |
|
1139
TETRA Technologies
TTI
$1.25B
| $20.8M | ﹤0.01% |
10,334,424
+167,549
| +2% | +$288K |
|
|
LDL
1140
DELISTED
Lydall, Inc.
LDL
| $20.6M | ﹤0.01% |
828,640
-3,883
| -0.5% | -$82.9K |
|
|
LOGM
1141
DELISTED
LogMein, Inc.
LOGM
| $20.6M | ﹤0.01% |
290,476
+5,084
| +2% | +$364K |
|
1142
Barings BDC
BBDC
$987M
| $20.5M | ﹤0.01% |
2,016,320
-18,590
| -0.9% | -$185K |
|
1143
Everest Group
EG
$14B
| $20.4M | ﹤0.01% |
76,683
-724
| -0.9% | -$183K |
|
1144
Regenxbio
RGNX
$704M
| $20.4M | ﹤0.01% |
572,958
-88,341
| -13% | -$3.58M |
|
1145
Stepan Co
SCL
$1.48B
| $20.2M | ﹤0.01% |
208,266
+8,487
| +4% | +$805K |
|
1146
Jack Henry & Associates
JKHY
$11.1B
| $20.1M | ﹤0.01% |
137,687
-161,519
| -54% | -$22.9M |
|
1147
Diageo
DEO
$52.8B
| $19.9M | ﹤0.01% |
121,535
+2,527
| +2% | +$423K |
|
1148
Molson Coors Class B
TAP
$7.85B
| $19.8M | ﹤0.01% |
344,820
+723
| +0.2% | +$39.2K |
|
1149
Natera
NTRA
$44.8B
| $19.7M | ﹤0.01% |
601,748
-240,720
| -29% | -$7.12M |
|
|
VAR
1150
DELISTED
Varian Medical Systems, Inc.
VAR
| $19.7M | ﹤0.01% |
165,438
-4,588
| -3% | -$546K |
|
Similar funds
T. Rowe Price Associates's Q3 2019 Portfolio in Review
As of Q3 2019, T. Rowe Price Associates held 2,592 positions worth $706B, down 0.8% from $712B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Trading was light in Q3 2019: portfolio turnover was 4.9%. T. Rowe Price Associates opened 52 new positions and exited 74, leaving the 2,592-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q3 2019 buy was The Southern Company: 9,440,159 shares worth $502M.
- T. Rowe Price Associates added most to Fidelity National Information Services in Q3 2019, an estimated $3.15B increase.
- T. Rowe Price Associates's biggest Q3 2019 reduction was Bank of America, cutting an estimated $1.43B.
- T. Rowe Price Associates fully exited Worldpay, Inc. in Q3 2019, selling an estimated $3.23B.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $706B portfolio in Q3 2019.
- T. Rowe Price Associates opened 52 new positions and closed 74 in Q3 2019.
- T. Rowe Price Associates's portfolio value fell 0.8% quarter-over-quarter to $706B.
Based on T. Rowe Price Associates's 13F filing for Q3 2019, filed 14 Nov 2019.